Pharmacological treatment of ankylosing spondylitis: A systematic review

Drugs

Volumn 65, Issue 15, 2005, Pages 2111-2127

  Boulos, Pauline ^a,e   Dougados, Maxime ^b   MacLeod, Stuart M ^c   Hunsche, Elke ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MERCK RESEARCH LABORATORIES   (United States)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; AMITRIPTYLINE; AZAPROPAZONE; BENOXAPROFEN; CELECOXIB; CORTICOSTEROID; ETORICOXIB; FENOPROFEN; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PENICILLAMINE; PHENYLBUTAZONE; PIRAZOLAC; PIROXICAM; SALAZOSULFAPYRIDINE; SULINDAC; TENOXICAM; TOLFENAMIC ACID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; XIMOPROFEN;

ABDOMINAL PAIN; ANKYLOSING SPONDYLITIS; ANOREXIA; ARTHRALGIA; ARTHRITIS; BACKACHE; CELLULITIS; CHOLECYSTITIS; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEVER; GASTROINTESTINAL TOXICITY; HEMIPARESIS; HUMAN; INGUINAL HERNIA; INSOMNIA; LEUKOCYTOSIS; LYMPHADENOPATHY; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; MYALGIA; NAUSEA; NEUROMA; PNEUMONIA; PURPURA; RASH; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; STOMACH ULCER; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; DIPHOSPHONATES; HUMANS; MEDLINE; RANDOMIZED CONTROLLED TRIALS; REVIEW LITERATURE; SPONDYLITIS, ANKYLOSING; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 26944469000     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565150-00004     Document Type: Review

References (111)

1. Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977; 237 (24): 2613-4
2. Boyer GS, Lanier AP, Templin DT. Prevalence rates of spondyloarthropathies, rheumatoid arthritis and other rheumatic disease in an Alaskan Inupiat Eskimo population. J Rheumatol 1988; 15 (4): 678-83
3. Bakland G, Gran JT, Nossent JC. Incidence and prevalence of ankylosing spondylitis in northern Norway [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S392
4. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41 (1): 58-67
5. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41 (5): 778-99
6. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985; 44 (6): 359-67
7. van der Heijde DMF, Wanders A, Spoorenberg A, et al. Structural damage assessed on radiographs in patients with ankylosing spondylitis (AS) steadily increases over time [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S175
8. Huscher D, Thiele K, Merkesdal S, et al. Comparison of the annual direct and indirect costs in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis [abstract]. Arthritis Rheum 2002; 46 (9 Suppl.): S93
9. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002; 46 (1): 223-31
10. Stone M, Bruckel J, Warren RW, et al. Progressive disability and functional impairment in females and males with ankylosing spondylitis is predicted by longer disease duration [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S172
11. Jadad A, Moore R, Carroll D, et al. Assessing the quality of reports on randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
12. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44 (8): 1876-86
13. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21 (12): 2286-91
14. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21 (12): 2281-5
15. Calin A, Nakache JP, Gueguen A, et al. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999; 38 (9): 878-82
16. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346 (18): 1349-56
17. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48 (6): 1667-75
18. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359 (9313): 1187-93
19. Caldwell JR, Altman RD, Burch FX, et al. Treatment of ankylosing spondylitis with oxaprozin: a comparison with in-domethicin. Semin Arthritis Rheum 1986; 15 (2 Suppl.): 95-100
20. Charlot J, Villiaumey J. A comparative study of benoxaprofen and ketoprofen in ankylosing spondylitis. Eur J Rheumatol Inflamm 1982; 5 (2): 277-81
21. Esdaile J, Rothwell R, MacLaughlin K, et al. Double-blind comparison of tolmetin sodium and indomethacin in ankylosing spondylitis. J Rheumatol 1982; 9 (1): 69-74
22. Calin A, Britton M. Sulindac in ankylosing spondylitis: double-blind evaluation of sulindac and indomethacin. JAMA 1979; 242 (17): 1885-6
23. Palferman TG, Webley M. A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm 1991; 11 (2): 23-9
24. Schwarzer AC, Cohen M, Arnold MH, et al. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Curr Med Res Opin 1990; 11 (10): 648-53
25. Santo JE, Queiroz MV. Oxaprozin versus diclofenac sodium in the treatment of ankylosing spondylitis. J Int Med Res 1988; 16 (2): 150-6
26. Doury P, Pattin S. Comparative study of the effectiveness of flurbiprofen given twice or 3-times daily. Curr Med Res Opin 1977; 5 (1): 127-9
27. Khan MA. A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. J Rheumatol 1987; 14 (1): 118-23
28. Melian A, van der Heijde DM, James MK, et al. Etoricoxib in the treatment of ankylosing spondylitis (AS) [abstract]. Arthritis Rheum 2002; 46 (9 Suppl.): S432
29. McKenna F. Efficacy of diclofenac/misoprostol vs diclofenac in the treatment of ankylosing spondylitis. Drugs 1993; 45 Suppl. 1: 24-30
30. Astorga G. Double-blind, parallel clinical trial of tenoxicam (Ro 12-0068) versus piroxicam in patients with ankylosing spondylitis. Eur J Rheumatol Inflamm 1987; 9 (2): 70-3
31. Siemens P. Fenbufen in the treatment of ankylosing spondylitis. Pharmacology 1982; 25 Suppl. 1: 51-3
32. Hill HF, Hill AG. Ankylosing spondylitis: open long-term and double-blind crossover studies with naproxen. J Clin Pharmacol 1975; 15 (4 Pt 2): 355-62
33. Liebling MR, Altman RD, Benedek TG, et al. A Double-blind, multiclinic trial of Sulindac (MD-213) in the treatment of ankylosing spondylitis [abstract]. Arthritis Rheum 1975; 18: 411
34. Godfrey RG, Calabro JJ, Mills D, et al. A double-blind cross-over trial of aspirin, indomethacin and phenylbutazone in ankylosing spondylitis [abstract]. Arthritis Rheum 1972; 15(1): 110
35. van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52 (4): 1205-15
36. Dougados M, Behier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44 (1): 180-5
37. Dougados M, Gueguen A, Nakache JP, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 1999; 38 (3): 235-44
38. Batlle-Gualda E, Figueroa M, Ivorra J, et al. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 1996; 23 (7): 1200-6
39. Villa Alcazar LF, de Buergo M, Rico LH, et al. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996; 23 (7): 1194-9
40. Dougados M, Nguyen M, Caporal R, et al. Ximoprofen in ankylosing spondylitis: a double blind placebo controlled dose ranging study. Scand J Rheumatol 1994; 23 (5): 243-8
41. Carcassi C, La Nasa G, Perpignano G. A 12-week double-blind study of the efficacy, safety and tolerance of pirazolac b.i.d. compared with indomethacin t.i.d. in patients with ankylosing spondylitis. Drugs Exp Clin Res 1990; 16 (1): 29-37
42. Dougados M, Caporal R, Doury P, et al. A double blind cross-over placebo controlled trial of ximoprofen in AS. J Rheumatol 1989; 16 (8): 1167-9
43. Dougados M, Nguyen M, Nakache JP, et al. Spondylarthrite ankylosante et anti-inflammatoires. Concours Med 1987; 109: 2780-6
44. Bird HA, Le Gallez P, Astbury C. A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. Pharmatherapeutica 1986; 4 (7): 457-62
45. Calabro JJ. Efficacy of diclofenac in ankylosing spondylitis. Am J Med 1986; 80 (4B): 58-63
46. Doury P, Roux H. Isoxicam vs ketoprofen in ankylosing spondylitis. Br J Clin Pharmacol 1986; 22 (2 Suppl.): 157S-60S
47. Franssen MJ, Gribnau FW, van de Putte LB. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clin Rheumatol 1986; 5 (2): 210-20
48. Lomen PL, Turner LF, Lamborn KR, et al. Flurbiprofen in the treatment of ankylosing spondylitis: a comparison with phenylbutazone. Am J Med 1986; 80 (3A): 120-6
49. Lomen PL, Turner LF, Lamborn KR, et al. Flurbiprofen in the treatment of ankylosing spondylitis: a comparison with in-domethacin. Am J Med 1986; 80 (3A): 127-32
50. Khan MA. Diclofenac in the treatment of ankylosing spondylitis: review of worldwide clinical experience and report of a double-blind comparison with indomethacin. Semin Arthritis Rheum 1985; 15 (2 Suppl. 1): 80-4
51. Armstrong RD, Laurent R, Panayi GS. A comparison of indoprofen and indomethacin in the treatment of ankylosing spondylitis. Pharmatherapeutica 1984; 3 (10): 637-41
52. Tannenbaum H, DeCoteoau WE, Esdaile J, et al. A double blind multicenter trial comparing piroxicam and indomethacin in ankylosing spondylitis with long-term follow-up. Curr Ther Res 1984; 36 (3): 426-35
53. Jajic I, Nekora A, Chadri HA. Pirprofene, indometacine et placebo dans la spondylarthrite ankylosante. Comparison en double insu. Nouv Presse Med 1982; 11 (33): 2491-3
54. Romberg O. Comparison of piroxicam with indomethacin in ankylosing spondylitis. Am J Med 1982; 73 Suppl.: 58-62
55. Sydnes OA. Comparison of piroxicam with indomethicin in ankylosing spondylitis: a double-blind crossover trial. Br J Clin Pract 1981; 35 (1): 40-4
56. Bird HA, Rhind VM, Pickup ME, et al. A comparative study of benoxaprofen and indomethacin in ankylosing spondylitis. J Rheumatol Suppl 1980; 6: 139-42
57. Burry HC, Siebers R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. N Z Med J 1980; 92 (670): 309-11
58. Nahir AM, Scharf Y. A comparative study of diclofenac and sulindac in ankylosing spondylitis. Rheumatol Rehabil 1980; 19 (3): 189-98
59. Rejholec V, Vapaatalo H, Tokola O, et al. Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin. Scand J Rheumatol Suppl 1980; 36: 1-7
60. Shipley M, Berry H, Bloom B. A double-blind cross-over trial of indomethacin, fenoprofen and placebo in ankylosing spondylitis, with comments on patient assessment. Rheumatol Rehabil 1980; 19 (2): 122-5
61. Wordsworth BP, Ebringer RW, Coggins E, et al. A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil 1980; 19 (4): 260-3
62. Ansell BM, Major G, Liyanage SP, et al. A comparative study of Butacote and Naprosyn in ankylosing spondylitis. Ann Rheum Dis 1978; 37 (5): 436-9
63. Mena HR, Willkens RF. Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone. Eur J Clin Pharmacol 1977; 11 (4): 263-6
64. Jessop JD. Double-blind study of ketoprofen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil 1976; Suppl.: 37-42
65. Treadwell BL, Tweed JM. Ketoprofen (Orudis) in ankylosing spondylitis. N Z Med J 1975; 81 (539): 411-3
66. Calcraft B, Tildesley G, Evans KT, et al. Azapropazone in the treatment of ankylosing spondylitis: a controlled clinical trial. Rheumatol Rehabil 1974; 13 (1): 23-9
67. Calin A, Grahame R. Double-bind cross-over trial of flurbiprofen and phenylbutazone in ankylosing spondylitis. BMJ 1974; 4 (5943): 496-9
68. Sturrock RD, Hart FD. Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 1974; 33 (2): 129-31
69. Wanders A, van der Heijde DM, Landewe R, et al. Inhibition of radiographic progression in ankylosing spondylitis (as) by continuous use of NSAIDS [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S233
70. Peters ND, Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 1992; 21 (3): 134-8
71. Luukkainen R, Nissila M, Asikainen E, et al. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 1999; 17 (1): 88-90
72. Maugars Y, Mathis C, Berthelot JM, et al. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 1996; 35 (8): 767-70
73. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42 (11): 2325-9
74. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39 (12): 2004-12
75. Kirwan J, Edwards A, Huitfeldt B, et al. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993; 32 (8): 729-33
76. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis: a radiological, clinical and laboratory assessment. Clin Rheumatol 1991; 10 (1): 43-8
77. Corkill MM, Jobanputra P, Gibson T, et al. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol 1990; 29 (1): 41-5
78. Ferraz MB, Tugwell P, Goldsmith CH, et al. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17 (11): 1482-6
79. Davis MJ, Dawes PT, Beswick E, et al. Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol 1989; 28 (5): 410-3
80. Nissila M, Lehtinen K, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of ankylosing spondylitis: a twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988; 31 (9): 1111-6
81. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. BMJ Clin Res Ed 1986; 293 (6552): 911-4
82. Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986; 45 (5): 396-9
83. Sansoni P, Passeri G, Fagnoni F, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995; 10 (11): 1719-25
84. Francis MD, Hovancik K, Boyce RW. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989; 11 (5): 239-52
85. Barbier A, Breliere JC, Remandet B, et al. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986; 45 (1): 67-74
86. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60mg versus 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46 (3): 766-73
87. Maksymowych W, Fitzgerald AA, LeClercq S, et al. A 6 month, randomized, controlled, double-blinded dose response com-parison of intravenous pamidronate (60mg vs 10mg) in the treatment of NSAID-refractory ankylosing spondylitis (AS) [abstract]. Arthritis Rheum 2001; 44 (9 Suppl.): S159
88. Jauregui E, Conner-Spady B, Russell AS, et al. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. J Rheumatol 2004; 31 (12): 2422-8
89. Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41 (6): 326-31
90. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNF alpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S34-7
91. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52 (2): 582-91
92. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63 (12): 1594-600
93. Davis Jr JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48 (11): 3230-6
94. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48 (4): 1126-36
95. Calin A, Dijkmans B, Emery P, et al. Assessments of disease activity and functionality by Enbrel-treated ankylosing spondylitis patients in a multicenter, placebo-controlled trial [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S172
96. van der Heijde D, Dougados M, Davis JC, et al. The effects of etanercept on patient-reported outcomes for subject with ankylosing spondylitis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S174
97. Brandt J, Kariouzov A, Listing J, et al. Six months results of a German double-blind placebo controlled, phase-III clinical trial of Etanercept in active ankylosing spondylitis [abstract]. Arthritis Rheum 2002; 46 (9 Suppl.): S429
98. Brandt J, Listing J, Alten R, et al. Quality of life improvement in patients with severe ankylosing spondylitis upon treatment with the anti-TNF alpha antibody infliximab in a placebo controlled multicenter trial [abstract]. Arthritis Rheum 2001; 44 (9 Suppl.): S89
99. Gorman JD, Sack KE, Davis JC. A randomized, double-blind, placebo-controlled trial of etanercept (ENBREL) in the treatment of ankylosing spondylitis [abstract]. Arthritis Rheum 2001; 44 (9 Suppl.): S90
100. Altan L, Bingol U, Karakoc Y, et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001; 30 (5): 255-9
101. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-del-Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, placebo-controlled, double-blind trial [abstract]. Arthritis Rheum 2002; 46 (9 Suppl.): S433
102. Roychowdhury B, Bintley-Bagot S, Bulgen DY, et al. Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) 2002; 41 (11): 1330-2
103. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31 (8): 1568-74
104. Koh WH, Pande I, Samuels A, et al. Low dose amitriptyline in ankylosing spondylitis: a short term, double blind, placebo controlled study. J Rheumatol 1997; 24 (11): 2158-61
105. Steven MM, Morrison M, Sturrock RD. Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial. J Rheumatol 1985; 12 (4): 735-7
106. Maksymowych WP, Inman RD, Gladman D, et al. Canadian Rheumatology Association consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003; 30 (6): 1356-63
107. Miceli-Richard C, Dougados M. NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S65-6
108. Jenkins JK, Seligman PJ. Memorandum: analysis and recommendation for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. April 6, 2005 [online]. Available from URL: http://www.fda.gov/cder/drug/ infopage/COX2/NSAIDdecisionMemo.pdf [Accessed 2005 Jun 16]
109. Marzo-Ortega H, McGonagle D, O'Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44 (9): 2112-7
110. Gregoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol 1995; 48 (1): 159-63
111. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309 (6964): 1286-91